Authors: Michael D Staehler Jessica Kruse Nicolas Haseke Thomas Stadler Alexander Roosen Alexander Karl Christian G Stief Karl W Jauch Christiane J Bruns
Publish Date: 2010/05/04
Volume: 28, Issue: 4, Pages: 543-547
Abstract
Eightyeight patients were identified with liver metastases and indication of surgery between 1995 and 2006 In 68 patients liver resection was performed 20 patients denied surgery and served as comparison group Patients were followed for survivalMedian age was 58 Median amount of liver metastases was 2 range 1–30 Median followup was 26 months range 1–187 In both groups 79 received systemic therapy The 5year overall survival rate OSR5 after metastasectomy was 622 ± 114 SEM with a median survival MS of 142 95 confidence interval CI 115–169 months OSR5 in the control group was 293 ± 220 SEM with a MS of 27 95 CI 16–38 months P = 0003 MS was 155 95 CI 133–175 months with metachronous metastases compared to 29 95 CI 25–33 months in the comparison group P = 0001 Lowgrade primary RCC had a MS of 155 95 CI 123–187 months compared to 29 95 CI 8–50 months without resection P = 00036 Highgrade RCC as well as patients with synchronous metastases did not benefit from surgeryLiver metastasectomy is an independent valuable tool in the treatment of metastatic RCC and significantly prolongs patient’s survival even if further systemic treatment is necessary With the evidence given patients may benefit from liver metastasis resection if technically feasible
Keywords: